These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27857264)

  • 21. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
    Sun Y; Kang E; Baek H; Jung J; Hwang E; Koo J; Kim EK; Kim SW
    Jpn J Clin Oncol; 2015 Jun; 45(6):527-32. PubMed ID: 25838294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability in Cancer Risk with BRCA Mutations.
    Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
    [No Abstract]   [Full Text] [Related]  

  • 27. BRCA1 and BRCA2 mutations in a South American population.
    Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
    Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
    Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
    Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
    [No Abstract]   [Full Text] [Related]  

  • 29. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
    Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
    Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
    Kast K; Schmutzler RK; Rhiem K; Kiechle M; Fischer C; Niederacher D; Arnold N; Grimm T; Speiser D; Schlegelberger B; Varga D; Horvath J; Beer M; Briest S; Meindl A; Engel C
    Int J Cancer; 2014 Nov; 135(10):2352-61. PubMed ID: 24700448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
    Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
    Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.
    Flippo-Morton T; Walsh K; Chambers K; Amacker-North L; White B; Sarantou T; Boselli DM; White RL
    Breast J; 2016; 22(1):35-44. PubMed ID: 26695813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
    Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
    Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA genes: BRCA 1 and BRCA 2.
    Varol U; Kucukzeybek Y; Alacacioglu A; Somali I; Altun Z; Aktas S; Oktay Tarhan M
    J BUON; 2018; 23(4):862-866. PubMed ID: 30358186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.